GLP-1 modulates actin polymerization, improving insulin sensitivity and glucose-stimulated insulin secretion Chronic hyperglycemia, or glucotoxicity, causes pancreatic cell dysfunction, diminished glucose-stimulated insulin secretion, and the production of long actin stress fibers 6,7
Your provider typically assesses HbA1c every three months during dose titration
article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)
Patience during titration is not optional
Additionally, to simulate sepsis caused by polymicrobial infection and assess the impact of GLP-1RAs, the study utilized a cecal content injection method
& Brierley, D
